Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...

Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...

“The meaningful changes seen in a short trial are very encouraging,” said Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio. “We are honored that Dr. Sharon Cohen will present our ...

INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a ...

INKmune® is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer ...

INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US. About INmune Bio Inc. (INMB) ...

“INKmune™ can be given to men with mCRPC in an out-patient setting and so far has an exemplary safety profile,” said RJ Tesi, MD CEO of INmune. “Data from the low dose cohort has shown ...

INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer.